Literature DB >> 11348892

Opioids in chronic non-malignant pain.

H McQuay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11348892      PMCID： PMC1120268          DOI： 10.1136/bmj.322.7295.1134

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  1 in total

1.  Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.

Authors:  L Allan; H Hays; N H Jensen; B L de Waroux; M Bolt; R Donald; E Kalso
Journal:  BMJ       Date:  2001-05-12
  1 in total
  5 in total

1.  Opioids in chronic non-malignant pain. Opioids can cause addiction even in patients with pain.

Authors:  J S Milledge
Journal:  BMJ       Date:  2001-09-08

2.  [Effective pain relief facilitates exercise therapy : Results of a multicenter study with controlled-release oxycodone in patients with movement pain].

Authors:  W Teske; A Anastasiadis; J Krämer; T Theodoridis
Journal:  Orthopade       Date:  2008-12       Impact factor: 1.087

3.  [Physicians' knowledge and attitudes concerning the use of opioids in the treatment of chronic cancer and non-cancer pain].

Authors:  M Pflughaupt; R Scharnagel; G Gossrau; U Kaiser; T Koch; R Sabatowski
Journal:  Schmerz       Date:  2010-06       Impact factor: 1.107

Review 4.  The role of opioid analgesics in rheumatoid disease in the elderly population.

Authors:  Norbert Griessinger; Reinhard Sittl; Robert Jost; Michael Schaefer; Rudolf Likar
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity.

Authors:  Paul R Chelminski; Timothy J Ives; Katherine M Felix; Steven D Prakken; Thomas M Miller; J Stephen Perhac; Robert M Malone; Mary E Bryant; Darren A DeWalt; Michael P Pignone
Journal:  BMC Health Serv Res       Date:  2005-01-13       Impact factor: 2.655
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.